Cargando…

Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine

BACKGROUND: Longer-term immune response data after 3 doses of coronavirus disease 2019 (COVID-19) mRNA vaccine remain limited, particularly among older adults and after Omicron breakthrough infection. METHODS: We quantified wild-type- and Omicron-specific serum immunoglobulin (Ig)G levels, angiotens...

Descripción completa

Detalles Bibliográficos
Autores principales: Mwimanzi, Francis, Lapointe, Hope R, Cheung, Peter K, Sang, Yurou, Yaseen, Fatima, Kalikawe, Rebecca, Datwani, Sneha, Burns, Laura, Young, Landon, Leung, Victor, Ennis, Siobhan, Brumme, Chanson J, Montaner, Julio S G, Dong, Winnie, Prystajecky, Natalie, Lowe, Christopher F, DeMarco, Mari L, Holmes, Daniel T, Simons, Janet, Niikura, Masahiro, Romney, Marc G, Brumme, Zabrina L, Brockman, Mark A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003738/
https://www.ncbi.nlm.nih.gov/pubmed/36910697
http://dx.doi.org/10.1093/ofid/ofad073
_version_ 1784904675113304064
author Mwimanzi, Francis
Lapointe, Hope R
Cheung, Peter K
Sang, Yurou
Yaseen, Fatima
Kalikawe, Rebecca
Datwani, Sneha
Burns, Laura
Young, Landon
Leung, Victor
Ennis, Siobhan
Brumme, Chanson J
Montaner, Julio S G
Dong, Winnie
Prystajecky, Natalie
Lowe, Christopher F
DeMarco, Mari L
Holmes, Daniel T
Simons, Janet
Niikura, Masahiro
Romney, Marc G
Brumme, Zabrina L
Brockman, Mark A
author_facet Mwimanzi, Francis
Lapointe, Hope R
Cheung, Peter K
Sang, Yurou
Yaseen, Fatima
Kalikawe, Rebecca
Datwani, Sneha
Burns, Laura
Young, Landon
Leung, Victor
Ennis, Siobhan
Brumme, Chanson J
Montaner, Julio S G
Dong, Winnie
Prystajecky, Natalie
Lowe, Christopher F
DeMarco, Mari L
Holmes, Daniel T
Simons, Janet
Niikura, Masahiro
Romney, Marc G
Brumme, Zabrina L
Brockman, Mark A
author_sort Mwimanzi, Francis
collection PubMed
description BACKGROUND: Longer-term immune response data after 3 doses of coronavirus disease 2019 (COVID-19) mRNA vaccine remain limited, particularly among older adults and after Omicron breakthrough infection. METHODS: We quantified wild-type- and Omicron-specific serum immunoglobulin (Ig)G levels, angiotensin-converting enzyme 2 displacement activities, and live virus neutralization up to 6 months after third dose in 116 adults aged 24–98 years who remained COVID-19 naive or experienced their first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during this time. RESULTS: Among the 78 participants who remained COVID-19 naive throughout follow up, wild-type- and Omicron-BA.1-specific IgG concentrations were comparable between younger and older adults, although BA.1-specific responses were consistently significantly lower than wild-type-specific responses in both groups. Wild-type- and BA.1-specific IgG concentrations declined at similar rates in COVID-19-naive younger and older adults, with median half-lives ranging from 69 to 78 days. Antiviral antibody functions declined substantially over time in COVID-19-naive individuals, particularly in older adults: by 6 months, BA.1-specific neutralization was undetectable in 96% of older adults, versus 56% of younger adults. Severe acute respiratory syndrome coronavirus 2 infection, experienced by 38 participants, boosted IgG levels and neutralization above those induced by vaccination alone. Nevertheless, BA.1-specific neutralization remained significantly lower than wild-type, with BA.5-specific neutralization lower still. Higher Omicron BA.1-specific neutralization 1 month after third dose was an independent correlate of lower SARS-CoV-2 infection risk. CONCLUSIONS: Results underscore the immune benefits of the third COVID-19 mRNA vaccine dose in adults of all ages and identify vaccine-induced Omicron-specific neutralization as a correlate of protective immunity. Systemic antibody responses and functions however, particularly Omicron-specific neutralization, decline rapidly in COVID-19-naive individuals, particularly in older adults, supporting the need for additional booster doses.
format Online
Article
Text
id pubmed-10003738
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-100037382023-03-11 Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine Mwimanzi, Francis Lapointe, Hope R Cheung, Peter K Sang, Yurou Yaseen, Fatima Kalikawe, Rebecca Datwani, Sneha Burns, Laura Young, Landon Leung, Victor Ennis, Siobhan Brumme, Chanson J Montaner, Julio S G Dong, Winnie Prystajecky, Natalie Lowe, Christopher F DeMarco, Mari L Holmes, Daniel T Simons, Janet Niikura, Masahiro Romney, Marc G Brumme, Zabrina L Brockman, Mark A Open Forum Infect Dis Major Article BACKGROUND: Longer-term immune response data after 3 doses of coronavirus disease 2019 (COVID-19) mRNA vaccine remain limited, particularly among older adults and after Omicron breakthrough infection. METHODS: We quantified wild-type- and Omicron-specific serum immunoglobulin (Ig)G levels, angiotensin-converting enzyme 2 displacement activities, and live virus neutralization up to 6 months after third dose in 116 adults aged 24–98 years who remained COVID-19 naive or experienced their first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during this time. RESULTS: Among the 78 participants who remained COVID-19 naive throughout follow up, wild-type- and Omicron-BA.1-specific IgG concentrations were comparable between younger and older adults, although BA.1-specific responses were consistently significantly lower than wild-type-specific responses in both groups. Wild-type- and BA.1-specific IgG concentrations declined at similar rates in COVID-19-naive younger and older adults, with median half-lives ranging from 69 to 78 days. Antiviral antibody functions declined substantially over time in COVID-19-naive individuals, particularly in older adults: by 6 months, BA.1-specific neutralization was undetectable in 96% of older adults, versus 56% of younger adults. Severe acute respiratory syndrome coronavirus 2 infection, experienced by 38 participants, boosted IgG levels and neutralization above those induced by vaccination alone. Nevertheless, BA.1-specific neutralization remained significantly lower than wild-type, with BA.5-specific neutralization lower still. Higher Omicron BA.1-specific neutralization 1 month after third dose was an independent correlate of lower SARS-CoV-2 infection risk. CONCLUSIONS: Results underscore the immune benefits of the third COVID-19 mRNA vaccine dose in adults of all ages and identify vaccine-induced Omicron-specific neutralization as a correlate of protective immunity. Systemic antibody responses and functions however, particularly Omicron-specific neutralization, decline rapidly in COVID-19-naive individuals, particularly in older adults, supporting the need for additional booster doses. Oxford University Press 2023-02-09 /pmc/articles/PMC10003738/ /pubmed/36910697 http://dx.doi.org/10.1093/ofid/ofad073 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Major Article
Mwimanzi, Francis
Lapointe, Hope R
Cheung, Peter K
Sang, Yurou
Yaseen, Fatima
Kalikawe, Rebecca
Datwani, Sneha
Burns, Laura
Young, Landon
Leung, Victor
Ennis, Siobhan
Brumme, Chanson J
Montaner, Julio S G
Dong, Winnie
Prystajecky, Natalie
Lowe, Christopher F
DeMarco, Mari L
Holmes, Daniel T
Simons, Janet
Niikura, Masahiro
Romney, Marc G
Brumme, Zabrina L
Brockman, Mark A
Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine
title Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine
title_full Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine
title_fullStr Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine
title_full_unstemmed Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine
title_short Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine
title_sort impact of age and severe acute respiratory syndrome coronavirus 2 breakthrough infection on humoral immune responses after three doses of coronavirus disease 2019 mrna vaccine
topic Major Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003738/
https://www.ncbi.nlm.nih.gov/pubmed/36910697
http://dx.doi.org/10.1093/ofid/ofad073
work_keys_str_mv AT mwimanzifrancis impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT lapointehoper impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT cheungpeterk impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT sangyurou impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT yaseenfatima impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT kalikawerebecca impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT datwanisneha impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT burnslaura impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT younglandon impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT leungvictor impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT ennissiobhan impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT brummechansonj impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT montanerjuliosg impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT dongwinnie impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT prystajeckynatalie impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT lowechristopherf impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT demarcomaril impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT holmesdanielt impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT simonsjanet impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT niikuramasahiro impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT romneymarcg impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT brummezabrinal impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine
AT brockmanmarka impactofageandsevereacuterespiratorysyndromecoronavirus2breakthroughinfectiononhumoralimmuneresponsesafterthreedosesofcoronavirusdisease2019mrnavaccine